Skip to main content
. 2012 Feb 16;7(2):e31752. doi: 10.1371/journal.pone.0031752

Table 4. Top 5 hits as therapeutic leads.

Gene Protein ‘Druggable’ Genome? Therapeutics?
TNFRSF9 tumor necrosis factor receptor superfamily, member 9 YES Agonist monoclonal (anti-CD137) in clinical trials [35]
SERPINI1 serpin peptidase inhibitor, clade I member 1 YES Related serine protease family inhibitors used clinically (aprotinin, A1AT)
RARRES1 retinoic acid receptor responder YES Up-regulated by tazarotene [36], FDA-approved drug
CLNS1A chloride channel, nucleotide- sensitive, 1A YES Multiple chloride channel enhancing drugs for CF [37]
TRIM10 tripartite motif-containing 10 YES Zinc/metal binding domain suggests chelator function; chelators picolinic acid, desferal in clinical use